Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.

Front Endocrinol (Lausanne) · 2023 · PMC10204114 · PMID 37229447

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

First, ICIs plus chemotherapy showed a trend toward better outcomes in terms of PFS, OS, and pCR, especially for the PD-L1 positive population.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.